IBD 50 and Sector Leaders member MiMedx ( MDXG ) is expected to report earnings on Feb. 23. MiMedx now trading 6% below the 17.57 buy point from a first-stage cup without handle that it cleared earlier.
[ibd-display-video id=2360792 width=50 float=left autostart=true] Keep in mind that it's risky to buy any stock just before it reports. You can reduce your exposure by waiting to see the actual numbers and the market's reaction.
MiMedx showed 33% EPS growth in its most recent report, while sales growth came in at 31%.
Analysts are looking for EPS growth of 42% for the quarter, and 45% growth for the full year. Annual growth estimates were recently revised lower.
Note: Dates for earnings reports are subject to change. Check the company's website for any updates.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.